Payment overview · 2025
General Payments
$689.33
50 reported records · 14 companies
Healthcare provider profile · identity verified
Drew David Schnyder, MD
Allopathic & Osteopathic Physicians|Family Medicine · ASHEVILLE, NC · NPI 1659402782
Verified facts
What the public records show
CMS Open Payments records show Drew David Schnyder, MD received $689.33 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 1708 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.30 | 23.4% | 24 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.56 | 17.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.86 | 15.7% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $45.34 | 6.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.43 | 6.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.45 | 5.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.80 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.36 | 4.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.06 | 3.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.63 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.32 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.86 | 2.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.84 | 2.1% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.52 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $689.33 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $142.12 | 23 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.67 | 21 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $76.23 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.74 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.74 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $61.52 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.04 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.04 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.12 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.12 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.45 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 1708 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
1708 | 1704 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 3223 | 2335 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 1916 | 1910 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 1708 | 1704 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 978 | 973 |
| Lisinopril | Lisinopril | 299 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 72 |
| Losartan Potassium | Losartan Potassium | 171 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 40 |
| Gabapentin | Gabapentin | 122 | 38 |
| Omeprazole | Omeprazole | 121 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 39 |
| Tramadol Hcl | Tramadol Hcl | 108 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 29 |
| Trazodone Hcl | Trazodone Hcl | 106 | 33 |
| Lorazepam | Lorazepam | 105 | 23 |
| Simvastatin | Simvastatin | 101 | 35 |
| Sertraline Hcl | Sertraline Hcl | 91 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 27 |
| Furosemide | Furosemide | 85 | 24 |
| Metformin Hcl Er | Metformin Hcl | 83 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 26 |
| Alprazolam | Alprazolam | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 27 |
| Eliquis | Apixaban | 77 | 20 |
| Clonazepam | Clonazepam | 76 | 22 |
| Meloxicam | Meloxicam | 71 | 28 |
| Metformin Hcl | Metformin Hcl | 71 | 23 |
| Jardiance | Empagliflozin | 66 | suppressed |
| Carvedilol | Carvedilol | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Finasteride | Finasteride | 51 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 14 |
| Temazepam | Temazepam | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 16 |
| Prednisone | Prednisone | 43 | 28 |
| Famotidine | Famotidine | 41 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 15 |
| Ozempic | Semaglutide | 37 | 11 |
| Allopurinol | Allopurinol | 36 | 12 |
| Potassium Chloride | Potassium Chloride | 36 | 15 |
| Diazepam | Diazepam | 34 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 32 | 32 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 15 | 12 |
| Baclofen | Baclofen | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 12 | 12 |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Havrix | Hepatitis A Virus Vaccine/Pf | 11 | 11 |
| Lybalvi | Olanzapine/Samidorphan Malate | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $689.33 · 50 records | ABBVIE INC. | ABRYSVO, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, GVOKE HYPOPEN, INCEPTIV, JARDIANCE, Leqembi, MOUNJARO, NURTEC ODT, OPSUMIT, Ohtuvayre, PREVNAR 20, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error